참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Tromethamine hydrochloride | HCID 93573 | — |
| 반응물 | Magnesium Chloride | HCID 5360315 | — |
| 반응물 | (E)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid | HCID 6519333 | — |
| 생성물 | Prostaglandin D2 | HCID 448457 | — |
반응 단계
To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 5 mM MgCl2) (0.2 ml) were added human platelet membrane fraction (0.1 mg) and 5 nM [3H]PGD2 (115Ci/mmol), and reacted at 4° C. for 90 min. After the reaction completed, the reaction mixture was filtered through the glass fiber filter paper, washed several times with cooled saline, and measured radioactivity retained on the filter paper. The specific binding was calculated by subtracting the non-specific binding (the binding in the presence of 10 μM PGD2) from the total binding. The binding-inhibitory activity of each compound was expressed as concentration required for 50% inhibition (IC50), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%. The results are shown in Table below.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US06172113B2 |
|---|
| 출처 데이터셋 | uspto-grants-2001_01 |
|---|
| ORD ID | ord-57997d1a926c4906a2673ed20f5ffceb |
|---|
| 출처 메모 | uspto-grants-2001_01 |
|---|